Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Telix Pharmaceuticals ( (AU:TLX) ) has issued an announcement.
Telix Pharmaceuticals announced the release of 47,256 ordinary shares from voluntary escrow, which were initially issued to Lightpoint Medical Limited as part of the acquisition of its SENSEI® radio-guided surgery business. This release, scheduled for 31 July 2025, is in accordance with ASX Listing Rule 3.10A and may impact Telix’s market operations by increasing the liquidity of its shares, potentially affecting stakeholder interests.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$31.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Headquartered in Melbourne, Australia, Telix operates internationally in the United States, Brazil, Canada, Europe, and Japan. The company is dedicated to addressing significant unmet medical needs in oncology and rare diseases.
Average Trading Volume: 1,331,989
Technical Sentiment Signal: Buy
Current Market Cap: A$8.55B
For an in-depth examination of TLX stock, go to TipRanks’ Overview page.